Abstract: The present invention discloses a topical cream composition of eflornithine or its pharmaceutically acceptable salts or prodrugs thereof with lavender oil as penetration enhancer and other excipients, which is effective to reduce the rate of skin hair growth and studies pertaining to pharmacodynamic behaviour thereof on hair growth rate. The invention further discloses a process for preparing a topical composition in the form of oil-in-water emulsion based cream composition which comprises eflornithine or its pharmaceutically acceptable salts or prodrugs thereof with a penetration enhancer and other excipients.

Abstract: The present invention discloses a sustained release non-aqueous injectable composition of buprenorphine, its metabolite, its prodrug, or its salt thereof for the treatment of moderate-to-severe pain and opioid dependence. The non-aqueous injectable composition includes one or more biocompatible non-aqueous solvents, one or more release retarding agents, one or more surfactants, one or more biodegradable polymers and one or more stabilizers. The buprenorphine composition of the present invention delivers buprenorphine over a period of about one week to 12 weeks after single administration which leads to better patient compliance by reducing the daily dose administration of buprenorphine. The present invention also provides an injectable composition with potentially less pain due to the use of smaller gauge needles wherein the suitable gauge of needle may be 23 gauge to 30 gauge with a length of 8 to 30 mm. The preferred size of needle is 25 to 30 gauge.

Abstract: Disclosed herein is an improved process for preparation of naltrexone decanoate under a monophasic medium using a single solvent by esterifying naltrexone with a decanoyl chloride in the presence of an organic base, wherein the solvent is preferably cyclo-pentyl-methyl-ether (CPME) which is non-toxic in nature. The invention further discloses the elimination of an impurity bis-decanoyl naltrexone obtained during the preparation of naltrexone decanoate by preparing acid addition salts of naltrexone decanoate and reconverting into naltrexone decanoate from its acid addition salts by neutralizing using a base in the presence of suitable solvent to obtain naltrexone decanoate with a purity of more than 99% The invention also discloses pharmaceutical composition of naltrexone decanoate with at least one pharmaceutically acceptable excipient and method of use of naltrexone decanoate for the treatment of opioid dependence, alcohol dependence for a period of 7 days to 90 days in a patient in need thereof.

Abstract: The invention discloses naltrexone implantable tablets which are devoid of metal salts and corticosteroids, and which provide consistent and controlled amount of naltrexone for 3 months or more; also disclosed is methods of treatment comprising the implants and methods of sterilization of the implants.

Abstract: The invention discloses naltrexone implantable tablets which are devoid of metal salts and corticosteroids, and which provide consistent and controlled amount of naltrexone for 3 months or more; also disclosed is methods of treatment comprising the implants and methods of sterilization of the implants.

Abstract: There is provided an efficient industrial process for the preparation of 21-cyclopropyl-7?-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydro-oripavine, i.e. buprenorphine of Formula-I in high yield and purity, with enhanced safety and eco-friendly norms. The invention further relates to an improved process for preparation of intermediates thereof in high yield and purity.

Abstract: There is provided an efficient industrial process for the preparation of 21-cyclopropyl-7?-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydro-oripavine, i.e. buprenorphine of Formula-I in high yield and purity, with enhanced safety and eco-friendly norms. The invention further relates to an improved process for preparation of intermediates thereof in high yield and purity.